Osteoarthritis Therapeutics Market Size, Share & Trends Analysis Report By Drug Type (NSAIDs, Corticosteroids), By Anatomy (Hip Osteoarthritis), By Route Of Administration (Topical Route, Oral Route), By Sales Channel, By End-use, By Region, And Segment F

Osteoarthritis Therapeutics Market Size, Share & Trends Analysis Report By Drug Type (NSAIDs, Corticosteroids), By Anatomy (Hip Osteoarthritis), By Route Of Administration (Topical Route, Oral Route), By Sales Channel, By End-use, By Region, And Segment Forecasts, 2025 - 2030


Drug Of Abuse Testing Services Market Growth & Trends

The global drug of abuse testing services market size is expected to reach USD 5.46 billion by 2030, registering a CAGR of 4.8% from 2025 to 2030, according to a new report by Grand View Research, Inc. The presence of a developed laboratory network and the prevalence of addiction are key drivers for market growth. Furthermore, the increasing trend of different drug use in the community and the importance of testing for the detection of illicit drugs and alcohol is expected to drive the demand. Thereby, continued test offering across the globe has fueled the growth.

Additionally, rising psychiatric disorders patients and hospitalizations due to the consumption of the drugs have boosted the demand. For instance, January 2023, National Survey on Drug Use and Health Results Detailing Mental Illness & Substance Use Levels (2021) was announced by SAMHSA. The survey mentioned that 16.5% of the aged 12 or older population (or 46.3 million) people had a substance use disorder wherein 29.5 million people were classified to have alcohol use disorder & 24 million people had drug use disorder.

In addition, the growing awareness among the population and the unmet need for treatment of addiction and illicit medication use among youth and adults is projected to boost the demand for the drug of abuse testing services industry. For instance, in August 2020, Averhealth announced the acquisition of the drug testing services of the Treatment Assessment Screening Center in Arizona. Therefore, increasing the focus of players to minimize the burden of addiction in emerging countries propels the market revenue. This factor has led companies to develop innovative and effective services for abuse cases.

Likewise, the COVID-19 pandemic has moderately impacted the market. During the pandemic, a constant demand for detection services was attributable to the increased addiction to Cannabis/Marijuana and opioids among the youth and adult population. According to United Nations Office on Drugs and Crime (UNODC), in 2020, around 275 million people used drugs worldwide, while according to the 2021 World Drug Report, over 36 million population suffered from drug use disorders. This factor has led to rising requirements for services post-pandemic.

Furthermore, the key participants are engaged in strategies such as agreements, mergers & acquisitions, partnerships, and launches, among others, to expand their global footprints and product portfolio. For instance, in December 2022, Urine Drugs of Abuse testing services was launched by Omega Laboratories in Canada. Adding to that from January 2023, the laboratory will offer urine testing to complement its molecular testing. The expansion of toxicology services will offer consumers an alternative to limited options available in Canada.

Drug Of Abuse Testing Services Market Report Highlights
  • The cannabis/marijuana segment captured the largest revenue share at 57.3% in 2024. Cannabis remains one of the most commonly consumed illicit substances globally.
  • The cannabis/marijuana segment is also likely to grow at a fastest CAGR of 5.5% over the forecast period.
  • North America drug of abuse testing services market dominated and accounted for a 51.1% share in 2024. The demand for drug testing is increasing due to factors like rising addiction rates, greater drug use in workplaces, and a higher incidence of accidents, along with established healthcare infrastructure.
  • Key players operating in the drug of abuse testing services constantly focus on product launches and geographical expansion to maintain their presence
Please note The report will be delivered in 2-3 business days upon order notification.


Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Drug Type
1.2.2. Anatomy
1.2.3. Route of Administration
1.2.4. Sales Channel
1.2.5. End Use
1.2.6. Regional scope
1.2.7. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in North America
1.4.5.2. Data for primary interviews in Europe
1.4.5.3. Data for primary interviews in Asia Pacific
1.4.5.4. Data for primary interviews in Latin America
1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Drug type outlook
2.2.2. Anatomy outlook
2.2.3. Route of administration outlook
2.2.4. Sales channel outlook
2.2.5. End use outlook
2.2.6. Regional outlook
2.3. Competitive Insights
Chapter 3. Osteoarthritis Therapeutics Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. High Prevalence of Osteoarthritis
3.2.1.2. Growing Aging Population
3.2.1.3. Technological Advancements
3.2.2. Market restraint analysis
3.2.2.1. Side Effects and Adverse Reactions
3.2.2.2. High cost of osteoarthritis therapeutics drugs
3.3. Osteoarthritis Therapeutics Market Analysis Tools
3.3.1. Industry Analysis – Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
3.3.3. Pricing Analysis
Chapter 4. Osteoarthritis Therapeutics Market: Drug Type Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Global Osteoarthritis Therapeutics Market by Drug Type Outlook
4.3. Global Osteoarthritis Therapeutics Market Size & Trend Analysis, by Drug Type, 2018 to 2030 (USD Million)
4.4. Viscosupplementation Agents
4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.5. Nonsteroidal Anti-inflammatory Drugs
4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.5.1.1. Naproxen
4.5.1.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.5.1.2. Aspirin
4.5.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.5.1.3. Diclofenac
4.5.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.5.1.4. Ibuprofen
4.5.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.5.1.5. Celecoxib
4.5.1.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.5.1.6. Meloxicam
4.5.1.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.5.1.7. Piroxicam
4.5.1.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.5.1.8. Ketoprofen
4.5.1.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.5.1.9. Other NSAIDs
4.5.1.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.5.2. Analgesics
4.5.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.5.2.1.1. Duloxetine
4.5.2.1.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.5.2.1.2. Acetaminophen
4.5.2.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.5.3. Corticosteroids
4.5.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.5.4. Others
4.5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 5. Osteoarthritis Therapeutics Market: Anatomy Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Global Osteoarthritis Therapeutics Market Movement Analysis
5.3. Global Osteoarthritis Therapeutics Market Size & Trend Analysis, by Anatomy, 2018 to 2030 (USD Million)
5.4. Knee Osteoarthritis
5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.5. Hip Osteoarthritis
5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.6. Hand Osteoarthritis
5.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.7. Others
5.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. Osteoarthritis Therapeutics Market: Route of Administration Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Global Osteoarthritis Therapeutics Market Movement Analysis
6.3. Global Osteoarthritis Therapeutics Market Size & Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
6.4. Parenteral Route
6.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.1.1. Hyaluronic Acid Injections
6.4.1.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.1.2. Corticosteroid Injections
6.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.1.3. Platelet-rich Plasma (PRP) Injections
6.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.1.4. Placental Tissue Matrix (PTM) Injections
6.4.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.1.5. Acetylsalicylic Acid (ASA) Injections
6.4.1.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.1.6. Others
6.4.1.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.5. Topical Route
6.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.6. Oral Route
6.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 7. Osteoarthritis Therapeutics Market: Sales Channel Estimates & Trend Analysis
7.1. Segment Dashboard
7.2. Global Osteoarthritis Therapeutics Market Movement Analysis
7.3. Global Osteoarthritis Therapeutics Market Size & Trend Analysis, by Sales Channel, 2018 to 2030 (USD Million)
7.4. Prescription Drugs
7.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
7.5. Over-the-Counter Drugs
7.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 8. Osteoarthritis Therapeutics Market: End Use Estimates & Trend Analysis
8.1. Segment Dashboard
8.2. Global Osteoarthritis Therapeutics Market Movement Analysis
8.3. Global Osteoarthritis Therapeutics Market Size & Trend Analysis, by End Use 2018 to 2030 (USD Million)
8.4. Hospital Pharmacies
8.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
8.5. Retail Pharmacies
8.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
8.6. Others
8.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 9. Osteoarthritis Therapeutics Market: Regional Estimates & Trend Analysis by
9.1. Regional Market Dashboard
9.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
9.3. North America
9.3.1. U.S.
9.3.1.1. Key country dynamics
9.3.1.2. Regulatory framework/ reimbursement structure
9.3.1.3. Competitive scenario
9.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
9.3.2. Canada
9.3.2.1. Key country dynamics
9.3.2.2. Regulatory framework/ reimbursement structure
9.3.2.3. Competitive scenario
9.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
9.3.3. Mexico
9.3.3.1. Key country dynamics
9.3.3.2. Regulatory framework/ reimbursement structure
9.3.3.3. Competitive scenario
9.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
9.4. Europe
9.4.1. UK
9.4.1.1. Key country dynamics
9.4.1.2. Regulatory framework/ reimbursement structure
9.4.1.3. Competitive scenario
9.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
9.4.2. Germany
9.4.2.1. Key country dynamics
9.4.2.2. Regulatory framework/ reimbursement structure
9.4.2.3. Competitive scenario
9.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
9.4.3. France
9.4.3.1. Key country dynamics
9.4.3.2. Regulatory framework/ reimbursement structure
9.4.3.3. Competitive scenario
9.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
9.4.4. Italy
9.4.4.1. Key country dynamics
9.4.4.2. Regulatory framework/ reimbursement structure
9.4.4.3. Competitive scenario
9.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
9.4.5. Spain
9.4.5.1. Key country dynamics
9.4.5.2. Regulatory framework/ reimbursement structure
9.4.5.3. Competitive scenario
9.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
9.4.6. Norway
9.4.6.1. Key country dynamics
9.4.6.2. Regulatory framework/ reimbursement structure
9.4.6.3. Competitive scenario
9.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
9.4.7. Sweden
9.4.7.1. Key country dynamics
9.4.7.2. Regulatory framework/ reimbursement structure
9.4.7.3. Competitive scenario
9.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
9.4.8. Denmark
9.4.8.1. Key country dynamics
9.4.8.2. Regulatory framework/ reimbursement structure
9.4.8.3. Competitive scenario
9.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
9.5. Asia Pacific
9.5.1. Japan
9.5.1.1. Key country dynamics
9.5.1.2. Regulatory framework/ reimbursement structure
9.5.1.3. Competitive scenario
9.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
9.5.2. China
9.5.2.1. Key country dynamics
9.5.2.2. Regulatory framework/ reimbursement structure
9.5.2.3. Competitive scenario
9.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
9.5.3. India
9.5.3.1. Key country dynamics
9.5.3.2. Regulatory framework/ reimbursement structure
9.5.3.3. Competitive scenario
9.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
9.5.4. Australia
9.5.4.1. Key country dynamics
9.5.4.2. Regulatory framework/ reimbursement structure
9.5.4.3. Competitive scenario
9.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
9.5.5. South Korea
9.5.5.1. Key country dynamics
9.5.5.2. Regulatory framework/ reimbursement structure
9.5.5.3. Competitive scenario
9.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
9.5.6. Thailand
9.5.6.1. Key country dynamics
9.5.6.2. Regulatory framework/ reimbursement structure
9.5.6.3. Competitive scenario
9.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
9.6. Latin America
9.6.1. Brazil
9.6.1.1. Key country dynamics
9.6.1.2. Regulatory framework/ reimbursement structure
9.6.1.3. Competitive scenario
9.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
9.6.2. Argentina
9.6.2.1. Key country dynamics
9.6.2.2. Regulatory framework/ reimbursement structure
9.6.2.3. Competitive scenario
9.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
9.7. MEA
9.7.1. South Africa
9.7.1.1. Key country dynamics
9.7.1.2. Regulatory framework/ reimbursement structure
9.7.1.3. Competitive scenario
9.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
9.7.2. Saudi Arabia
9.7.2.1. Key country dynamics
9.7.2.2. Regulatory framework/ reimbursement structure
9.7.2.3. Competitive scenario
9.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
9.7.3. UAE
9.7.3.1. Key country dynamics
9.7.3.2. Regulatory framework/ reimbursement structure
9.7.3.3. Competitive scenario
9.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
9.7.4. Kuwait
9.7.4.1. Key country dynamics
9.7.4.2. Regulatory framework/ reimbursement structure
9.7.4.3. Competitive scenario
9.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 10. Competitive Landscape
10.1. Recent Developments & Impact Analysis, By Key Market Participants
10.2. Company/Competition Categorization
10.3. Vendor Landscape
10.3.1. List of key distributors and channel partners
10.3.2. Key customers
10.3.3. Key company market share analysis, 2024
10.3.4. Sanofi SA
10.3.4.1. Company overview
10.3.4.2. Financial performance
10.3.4.3. Product benchmarking
10.3.4.4. Strategic initiatives
10.3.5. GlaxoSmithKline plc
10.3.5.1. Company overview
10.3.5.2. Financial performance
10.3.5.3. Product benchmarking
10.3.5.4. Strategic initiatives
10.3.6. Pfizer Inc.
10.3.6.1. Company overview
10.3.6.2. Financial performance
10.3.6.3. Product benchmarking
10.3.6.4. Strategic initiatives
10.3.7. Bayer AG
10.3.7.1. Company overview
10.3.7.2. Financial performance
10.3.7.3. Product benchmarking
10.3.7.4. Strategic initiatives
10.3.8. Zimmer Biomet
10.3.8.1. Company overview
10.3.8.2. Financial performance
10.3.8.3. Product benchmarking
10.3.8.4. Strategic initiatives
10.3.9. Novartis AG
10.3.9.1. Company overview
10.3.9.2. Financial performance
10.3.9.3. Product benchmarking
10.3.9.4. Strategic initiatives
10.3.10. Anika Therapeutics
10.3.10.1. Company overview
10.3.10.2. Financial performance
10.3.10.3. Product benchmarking
10.3.10.4. Strategic initiatives
10.3.11. Assertio Therapeutics, Inc.
10.3.11.1. Company overview
10.3.11.2. Financial performance
10.3.11.3. Product benchmarking
10.3.11.4. Strategic initiatives
10.3.12. Bioventus
10.3.12.1. Company overview
10.3.12.2. Financial performance
10.3.12.3. Product benchmarking
10.3.12.4. Strategic initiatives
10.3.13. Ferring Pharmaceuticals Inc.
10.3.13.1. Company overview
10.3.13.2. Financial performance
10.3.13.3. Product benchmarking
10.3.13.4. Strategic initiatives

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings